Specialty pharmacy will be the future of ScripsAmerica. After the 10K is filed all SCRC needs to do is show generated revenues each month. The statement in the corporate statement referring to expanding the number of States and pharmacies is encouraging. It's called focus. For the last several months we heard about RapiMeds, Diabetes Program, Dispensing, etc. The acting management team has now provided a single business focus - specialty pharmacy. It seems to me PIMD will be the main focus. Although we still don't know the PIMD, compounding, & Dispensing numbers through July, I believe there are revenues being generated and SCRC will demonstrate growth and profitability in the months to come. I am still in a wait and see mode, but the future of the SCRC looks promising.